Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 18/20 | 0.74 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.60 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19840647 | 1.00 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21337022 | 1.00 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL26849279 | 0.95 | FOLH1 (0.71) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL30185955 | 0.95 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL25741232 | 0.95 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL21344719 | 0.90 | FOLH1 (0.72) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18655461 | 0.88 | FOLH1 (0.74) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18059393 | 0.88 | FOLH1 (0.69) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18800235 | 0.87 | FOLH1 (0.76) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL23252356 | 0.87 | FOLH1 (0.67) | FOLH1NAALAD2RIMKLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814365-B2 | PSMA targeted fluorescent agents for image guided surgery | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-9878980-B2 | Heterodimers of glutamic acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2017-02-16 | — | — | US | disclosed |
| US-20160346410-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | MOLECULAR INSIGHT PHARMACEUTICALS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| EP-2921482-A2 | Labeled inhibitors of prostate-specific membrane antigen (PSMA), biological evaluation, and use as imaging agents | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160346410-A1 | TRIAZINE BASED RADIOPHARMACEUTICALS AND RADIOIMAGING AGENTS | PSMA5, PSMA2, PSMA1 | FOLH1 7/4885NAALAD2 80/4885RIMKLA 1653/4885 |
| US-11814365-B2 | PSMA targeted fluorescent agents for image guided surgery | KLK3, FOLH1, SPR | FOLH1 2/4885NAALAD2 211/4885RIMKLA 1680/4885 |
| US-20170044098-A1 | Heterodimers of Glutamic Acid | DDO, GLUL, ASNS | FOLH1 5/4885NAALAD2 9/4885RIMKLA 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.